世界の神経内分泌腫瘍治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Neuroendocrine Tumor Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4567 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、神経内分泌腫瘍治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（エベロリムス、スニチニブ、ドタオクトレオテート、ランレオチド、オクトレオチド）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・神経内分泌腫瘍治療の市場動向 ・企業の競争状況、市場シェア ・神経内分泌腫瘍治療の種類別市場規模と予測2016-2027（エベロリムス、スニチニブ、ドタオクトレオテート、ランレオチド、オクトレオチド） ・神経内分泌腫瘍治療の用途別市場規模と予測2016-2027（病院、クリニック、その他） ・神経内分泌腫瘍治療の北米市場規模2016-2027（アメリカ、カナダ） ・神経内分泌腫瘍治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・神経内分泌腫瘍治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・神経内分泌腫瘍治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・神経内分泌腫瘍治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Exelixis, Inc.、Advanced Accelerator Applications、Dauntless Pharmaceuticals, Inc.、Hutchinson Medipharma Limited、Ispen、Novartis AG、Progenics Pharmaceuticals, Inc.、Tarveda Therapeutics） ・結論

Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.

Market Analysis and Insights: Global Neuroendocrine Tumor Treatment Market
The global Neuroendocrine Tumor Treatment market size is projected to reach US$ 2302.3 million by 2027, from US$ 1495.4 million in 2020, at a CAGR of 5.9% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neuroendocrine Tumor Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neuroendocrine Tumor Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neuroendocrine Tumor Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neuroendocrine Tumor Treatment market.

Global Neuroendocrine Tumor Treatment Scope and Market Size
Neuroendocrine Tumor Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neuroendocrine Tumor Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Everolimus
Sunitinib
Lu-Dotatate
Lanreotide
Octreotide

Segment by Application
Hospitals
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Exelixis, Inc.
Advanced Accelerator Applications
Dauntless Pharmaceuticals, Inc.
Hutchinson Medipharma Limited
Ispen
Novartis AG
Progenics Pharmaceuticals, Inc.
Tarveda Therapeutics

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuroendocrine Tumor Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Everolimus
1.2.3 Sunitinib
1.2.4 Lu-Dotatate
1.2.5 Lanreotide
1.2.6 Octreotide
1.3 Market by Application
1.3.1 Global Neuroendocrine Tumor Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Neuroendocrine Tumor Treatment Market Perspective (2016-2027)
2.2 Neuroendocrine Tumor Treatment Growth Trends by Regions
2.2.1 Neuroendocrine Tumor Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neuroendocrine Tumor Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Neuroendocrine Tumor Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Neuroendocrine Tumor Treatment Industry Dynamic
2.3.1 Neuroendocrine Tumor Treatment Market Trends
2.3.2 Neuroendocrine Tumor Treatment Market Drivers
2.3.3 Neuroendocrine Tumor Treatment Market Challenges
2.3.4 Neuroendocrine Tumor Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Neuroendocrine Tumor Treatment Players by Revenue
3.1.1 Global Top Neuroendocrine Tumor Treatment Players by Revenue (2016-2021)
3.1.2 Global Neuroendocrine Tumor Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Neuroendocrine Tumor Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neuroendocrine Tumor Treatment Revenue
3.4 Global Neuroendocrine Tumor Treatment Market Concentration Ratio
3.4.1 Global Neuroendocrine Tumor Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuroendocrine Tumor Treatment Revenue in 2020
3.5 Neuroendocrine Tumor Treatment Key Players Head office and Area Served
3.6 Key Players Neuroendocrine Tumor Treatment Product Solution and Service
3.7 Date of Enter into Neuroendocrine Tumor Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Neuroendocrine Tumor Treatment Breakdown Data by Type
4.1 Global Neuroendocrine Tumor Treatment Historic Market Size by Type (2016-2021)
4.2 Global Neuroendocrine Tumor Treatment Forecasted Market Size by Type (2022-2027)

5 Neuroendocrine Tumor Treatment Breakdown Data by Application
5.1 Global Neuroendocrine Tumor Treatment Historic Market Size by Application (2016-2021)
5.2 Global Neuroendocrine Tumor Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Neuroendocrine Tumor Treatment Market Size (2016-2027)
6.2 North America Neuroendocrine Tumor Treatment Market Size by Type
6.2.1 North America Neuroendocrine Tumor Treatment Market Size by Type (2016-2021)
6.2.2 North America Neuroendocrine Tumor Treatment Market Size by Type (2022-2027)
6.2.3 North America Neuroendocrine Tumor Treatment Market Size by Type (2016-2027)
6.3 North America Neuroendocrine Tumor Treatment Market Size by Application
6.3.1 North America Neuroendocrine Tumor Treatment Market Size by Application (2016-2021)
6.3.2 North America Neuroendocrine Tumor Treatment Market Size by Application (2022-2027)
6.3.3 North America Neuroendocrine Tumor Treatment Market Size by Application (2016-2027)
6.4 North America Neuroendocrine Tumor Treatment Market Size by Country
6.4.1 North America Neuroendocrine Tumor Treatment Market Size by Country (2016-2021)
6.4.2 North America Neuroendocrine Tumor Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Neuroendocrine Tumor Treatment Market Size (2016-2027)
7.2 Europe Neuroendocrine Tumor Treatment Market Size by Type
7.2.1 Europe Neuroendocrine Tumor Treatment Market Size by Type (2016-2021)
7.2.2 Europe Neuroendocrine Tumor Treatment Market Size by Type (2022-2027)
7.2.3 Europe Neuroendocrine Tumor Treatment Market Size by Type (2016-2027)
7.3 Europe Neuroendocrine Tumor Treatment Market Size by Application
7.3.1 Europe Neuroendocrine Tumor Treatment Market Size by Application (2016-2021)
7.3.2 Europe Neuroendocrine Tumor Treatment Market Size by Application (2022-2027)
7.3.3 Europe Neuroendocrine Tumor Treatment Market Size by Application (2016-2027)
7.4 Europe Neuroendocrine Tumor Treatment Market Size by Country
7.4.1 Europe Neuroendocrine Tumor Treatment Market Size by Country (2016-2021)
7.4.2 Europe Neuroendocrine Tumor Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Neuroendocrine Tumor Treatment Market Size (2016-2027)
8.2 Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Type
8.2.1 Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Application
8.3.1 Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Region
8.4.1 Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Neuroendocrine Tumor Treatment Market Size (2016-2027)
9.2 Latin America Neuroendocrine Tumor Treatment Market Size by Type
9.2.1 Latin America Neuroendocrine Tumor Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Neuroendocrine Tumor Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Neuroendocrine Tumor Treatment Market Size by Type (2016-2027)
9.3 Latin America Neuroendocrine Tumor Treatment Market Size by Application
9.3.1 Latin America Neuroendocrine Tumor Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Neuroendocrine Tumor Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Neuroendocrine Tumor Treatment Market Size by Application (2016-2027)
9.4 Latin America Neuroendocrine Tumor Treatment Market Size by Country
9.4.1 Latin America Neuroendocrine Tumor Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Neuroendocrine Tumor Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Neuroendocrine Tumor Treatment Market Size (2016-2027)
10.2 Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Type
10.2.1 Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Application
10.3.1 Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Country
10.4.1 Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Exelixis, Inc.
11.1.1 Exelixis, Inc. Company Details
11.1.2 Exelixis, Inc. Business Overview
11.1.3 Exelixis, Inc. Neuroendocrine Tumor Treatment Introduction
11.1.4 Exelixis, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2016-2021)
11.1.5 Exelixis, Inc. Recent Development
11.2 Advanced Accelerator Applications
11.2.1 Advanced Accelerator Applications Company Details
11.2.2 Advanced Accelerator Applications Business Overview
11.2.3 Advanced Accelerator Applications Neuroendocrine Tumor Treatment Introduction
11.2.4 Advanced Accelerator Applications Revenue in Neuroendocrine Tumor Treatment Business (2016-2021)
11.2.5 Advanced Accelerator Applications Recent Development
11.3 Dauntless Pharmaceuticals, Inc.
11.3.1 Dauntless Pharmaceuticals, Inc. Company Details
11.3.2 Dauntless Pharmaceuticals, Inc. Business Overview
11.3.3 Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Introduction
11.3.4 Dauntless Pharmaceuticals, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2016-2021)
11.3.5 Dauntless Pharmaceuticals, Inc. Recent Development
11.4 Hutchinson Medipharma Limited
11.4.1 Hutchinson Medipharma Limited Company Details
11.4.2 Hutchinson Medipharma Limited Business Overview
11.4.3 Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Introduction
11.4.4 Hutchinson Medipharma Limited Revenue in Neuroendocrine Tumor Treatment Business (2016-2021)
11.4.5 Hutchinson Medipharma Limited Recent Development
11.5 Ispen
11.5.1 Ispen Company Details
11.5.2 Ispen Business Overview
11.5.3 Ispen Neuroendocrine Tumor Treatment Introduction
11.5.4 Ispen Revenue in Neuroendocrine Tumor Treatment Business (2016-2021)
11.5.5 Ispen Recent Development
11.6 Novartis AG
11.6.1 Novartis AG Company Details
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Neuroendocrine Tumor Treatment Introduction
11.6.4 Novartis AG Revenue in Neuroendocrine Tumor Treatment Business (2016-2021)
11.6.5 Novartis AG Recent Development
11.7 Progenics Pharmaceuticals, Inc.
11.7.1 Progenics Pharmaceuticals, Inc. Company Details
11.7.2 Progenics Pharmaceuticals, Inc. Business Overview
11.7.3 Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Introduction
11.7.4 Progenics Pharmaceuticals, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2016-2021)
11.7.5 Progenics Pharmaceuticals, Inc. Recent Development
11.8 Tarveda Therapeutics
11.8.1 Tarveda Therapeutics Company Details
11.8.2 Tarveda Therapeutics Business Overview
11.8.3 Tarveda Therapeutics Neuroendocrine Tumor Treatment Introduction
11.8.4 Tarveda Therapeutics Revenue in Neuroendocrine Tumor Treatment Business (2016-2021)
11.8.5 Tarveda Therapeutics Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Neuroendocrine Tumor Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Everolimus
Table 3. Key Players of Sunitinib
Table 4. Key Players of Lu-Dotatate
Table 5. Key Players of Lanreotide
Table 6. Key Players of Octreotide
Table 7. Global Neuroendocrine Tumor Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Neuroendocrine Tumor Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Neuroendocrine Tumor Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Neuroendocrine Tumor Treatment Market Share by Regions (2016-2021)
Table 11. Global Neuroendocrine Tumor Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Neuroendocrine Tumor Treatment Market Share by Regions (2022-2027)
Table 13. Neuroendocrine Tumor Treatment Market Trends
Table 14. Neuroendocrine Tumor Treatment Market Drivers
Table 15. Neuroendocrine Tumor Treatment Market Challenges
Table 16. Neuroendocrine Tumor Treatment Market Restraints
Table 17. Global Neuroendocrine Tumor Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Neuroendocrine Tumor Treatment Market Share by Players (2016-2021)
Table 19. Global Top Neuroendocrine Tumor Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Tumor Treatment as of 2020)
Table 20. Ranking of Global Top Neuroendocrine Tumor Treatment Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Neuroendocrine Tumor Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Neuroendocrine Tumor Treatment Product Solution and Service
Table 24. Date of Enter into Neuroendocrine Tumor Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neuroendocrine Tumor Treatment Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Neuroendocrine Tumor Treatment Revenue Market Share by Type (2016-2021)
Table 28. Global Neuroendocrine Tumor Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Neuroendocrine Tumor Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Neuroendocrine Tumor Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Neuroendocrine Tumor Treatment Revenue Market Share by Application (2016-2021)
Table 32. Global Neuroendocrine Tumor Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Neuroendocrine Tumor Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Neuroendocrine Tumor Treatment Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Neuroendocrine Tumor Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Neuroendocrine Tumor Treatment Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Neuroendocrine Tumor Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Neuroendocrine Tumor Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Neuroendocrine Tumor Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Neuroendocrine Tumor Treatment Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Neuroendocrine Tumor Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Neuroendocrine Tumor Treatment Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Neuroendocrine Tumor Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Neuroendocrine Tumor Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Neuroendocrine Tumor Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Neuroendocrine Tumor Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Neuroendocrine Tumor Treatment Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Neuroendocrine Tumor Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Neuroendocrine Tumor Treatment Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Neuroendocrine Tumor Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Neuroendocrine Tumor Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Neuroendocrine Tumor Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Neuroendocrine Tumor Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 64. Exelixis, Inc. Company Details
Table 65. Exelixis, Inc. Business Overview
Table 66. Exelixis, Inc. Neuroendocrine Tumor Treatment Product
Table 67. Exelixis, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2016-2021) & (US$ Million)
Table 68. Exelixis, Inc. Recent Development
Table 69. Advanced Accelerator Applications Company Details
Table 70. Advanced Accelerator Applications Business Overview
Table 71. Advanced Accelerator Applications Neuroendocrine Tumor Treatment Product
Table 72. Advanced Accelerator Applications Revenue in Neuroendocrine Tumor Treatment Business (2016-2021) & (US$ Million)
Table 73. Advanced Accelerator Applications Recent Development
Table 74. Dauntless Pharmaceuticals, Inc. Company Details
Table 75. Dauntless Pharmaceuticals, Inc. Business Overview
Table 76. Dauntless Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Product
Table 77. Dauntless Pharmaceuticals, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2016-2021) & (US$ Million)
Table 78. Dauntless Pharmaceuticals, Inc. Recent Development
Table 79. Hutchinson Medipharma Limited Company Details
Table 80. Hutchinson Medipharma Limited Business Overview
Table 81. Hutchinson Medipharma Limited Neuroendocrine Tumor Treatment Product
Table 82. Hutchinson Medipharma Limited Revenue in Neuroendocrine Tumor Treatment Business (2016-2021) & (US$ Million)
Table 83. Hutchinson Medipharma Limited Recent Development
Table 84. Ispen Company Details
Table 85. Ispen Business Overview
Table 86. Ispen Neuroendocrine Tumor Treatment Product
Table 87. Ispen Revenue in Neuroendocrine Tumor Treatment Business (2016-2021) & (US$ Million)
Table 88. Ispen Recent Development
Table 89. Novartis AG Company Details
Table 90. Novartis AG Business Overview
Table 91. Novartis AG Neuroendocrine Tumor Treatment Product
Table 92. Novartis AG Revenue in Neuroendocrine Tumor Treatment Business (2016-2021) & (US$ Million)
Table 93. Novartis AG Recent Development
Table 94. Progenics Pharmaceuticals, Inc. Company Details
Table 95. Progenics Pharmaceuticals, Inc. Business Overview
Table 96. Progenics Pharmaceuticals, Inc. Neuroendocrine Tumor Treatment Product
Table 97. Progenics Pharmaceuticals, Inc. Revenue in Neuroendocrine Tumor Treatment Business (2016-2021) & (US$ Million)
Table 98. Progenics Pharmaceuticals, Inc. Recent Development
Table 99. Tarveda Therapeutics Company Details
Table 100. Tarveda Therapeutics Business Overview
Table 101. Tarveda Therapeutics Revenue in Neuroendocrine Tumor Treatment Business (2016-2021) & (US$ Million)
Table 102. Tarveda Therapeutics Recent Development
Table 103. Research Programs/Design for This Report
Table 104. Key Data Information from Secondary Sources
Table 105. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuroendocrine Tumor Treatment Market Share by Type: 2020 VS 2027
Figure 2. Everolimus Features
Figure 3. Sunitinib Features
Figure 4. Lu-Dotatate Features
Figure 5. Lanreotide Features
Figure 6. Octreotide Features
Figure 7. Global Neuroendocrine Tumor Treatment Market Share by Application: 2020 VS 2027
Figure 8. Hospitals Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Neuroendocrine Tumor Treatment Report Years Considered
Figure 12. Global Neuroendocrine Tumor Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Neuroendocrine Tumor Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Neuroendocrine Tumor Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Neuroendocrine Tumor Treatment Market Share by Regions (2022-2027)
Figure 16. Global Neuroendocrine Tumor Treatment Market Share by Players in 2020
Figure 17. Global Top Neuroendocrine Tumor Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Tumor Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Neuroendocrine Tumor Treatment Revenue in 2020
Figure 19. Global Neuroendocrine Tumor Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Neuroendocrine Tumor Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Neuroendocrine Tumor Treatment Market Share by Type (2016-2027)
Figure 23. North America Neuroendocrine Tumor Treatment Market Share by Application (2016-2027)
Figure 24. North America Neuroendocrine Tumor Treatment Market Share by Country (2016-2027)
Figure 25. United States Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Neuroendocrine Tumor Treatment Market Share by Type (2016-2027)
Figure 29. Europe Neuroendocrine Tumor Treatment Market Share by Application (2016-2027)
Figure 30. Europe Neuroendocrine Tumor Treatment Market Share by Country (2016-2027)
Figure 31. Germany Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Neuroendocrine Tumor Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Neuroendocrine Tumor Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Neuroendocrine Tumor Treatment Market Share by Region (2016-2027)
Figure 41. China Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Neuroendocrine Tumor Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Neuroendocrine Tumor Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Neuroendocrine Tumor Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Neuroendocrine Tumor Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Neuroendocrine Tumor Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Neuroendocrine Tumor Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Neuroendocrine Tumor Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Exelixis, Inc. Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2016-2021)
Figure 61. Advanced Accelerator Applications Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2016-2021)
Figure 62. Dauntless Pharmaceuticals, Inc. Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2016-2021)
Figure 63. Hutchinson Medipharma Limited Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2016-2021)
Figure 64. Ispen Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2016-2021)
Figure 65. Novartis AG Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2016-2021)
Figure 66. Progenics Pharmaceuticals, Inc. Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2016-2021)
Figure 67. Tarveda Therapeutics Revenue Growth Rate in Neuroendocrine Tumor Treatment Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

---